

Publisher: John Wiley & Sons Inc
E-ISSN: 1097-0142|121|12|1917-1926
ISSN: 0008-543x
Source: CANCER, Vol.121, Iss.12, 2015-06, pp. : 1917-1926
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Ofatumumab for the treatment of chronic lymphocytic leukemia
Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. :








State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia
Oncology Research and Treatment, Vol. 39, Iss. 1-2, 2016-0 ,pp. :